Foot and mouth disease virus type A broad-spectrum neutralizing swine monoclonal antibody and application thereof

The pig-derived monoclonal antibody PAF56 was screened through high-throughput methods, which solved the broad-spectrum neutralization problem caused by the structural mutation of Foot-and-mouth disease virus type A antigen, achieved the neutralization effect on multiple strains, and prevented and controlled Foot-and-mouth disease diseases and Diagnosis provides effective tools.

CN118955700AActive Publication Date: 2024-11-15LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Patent Information

Application Number
CN202411058226.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

The antigen structure of Foot-and-mouth disease virus type A is relatively mutated, making it difficult to obtain broad-spectrum neutralizing antibodies, limiting the prevention, control and diagnosis of Foot-and-mouth disease.

Method used

A single B-cell antibody library was established using a high-throughput method, and a porcine monoclonal antibody specific for amino acid sequences of heavy and light chain variable regions was screened and obtained, which was able to neutralize multiple A-type FMDV strains and identify key antigen sites. Point the D72 site of the B-C loop of VP2.

Benefits of technology

PAF56 antibody shows broad spectrum neutralization activity, has high affinity for AF72 and SEA97 strains in A22 lineage, A/WH/CHA/09 and A/GDMM/2013 strains, providing effective use in the prevention and control and diagnosis of foot-and-mouth disease. tool.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses a foot-and-mouth disease virus type A broad-spectrum neutralizing swine monoclonal antibody and application of the foot-and-mouth disease virus type A broad-spectrum neutralizing swine monoclonal antibody. The amino acid sequence of a heavy chain variable region of the antibody PAF56 is shown as SEQ ID No.12, the sequence of a heavy chain CDR1 is GFGFSNTY, the sequence of a heavy chain CDR2 is VFTGGGAT, and the sequence of a heavy chain CDR3 is VSNRDGFGGVGNV. An amino acid sequence of a light chain variable region is shown as SEQ ID No.13, a light chain CDR1 sequence is SGSVTSLNY, a light chain CDR2 sequence is RTN, and a light chain CDR3 sequence is ALYKGSGTDTNI. The antibody PAF56 can be used for simultaneously neutralizing an AF72 strain of an A22 pedigree, and has A-type FMDV broad-spectrum neutralizing activity with A / WH / CHA / 09 and A / GDMM / 2013 epidemic strains of a domestic SEA97 pedigree. PAF56 recognizes an antigen site 2 of a VP2 B-C ring, a key amino acid is VP2 D72, and the recognized site is highly conserved in A-type FMDV. According to the invention, one natural host source type A specific FMDV broad-spectrum neutralizing antibody is obtained for the first time, and a key antigen site identified by the antibody is identified, so that a powerful tool is provided for establishment of FMDV antigen structure analysis and serological detection methods.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to a broad-spectrum neutralizing porcine monoclonal antibody of foot-and-mouth disease virus type A and application thereof. Background Art

[0002] Foot-and-mouth disease (FMD) is a highly contagious disease that harms even-toed ungulates such as cattle, pigs and sheep, restricting the development of international trade in animals and animal products, and seriously affecting the breeding industry of various countries. The pathogenic foot-and-mouth disease virus (FMDV) has seven serotypes: A, O, C, Asia1, SAT1, 2 and 3. Among them, the antigenic structure variation of type A FMDV is the largest, so it is difficult to obtain broad-spectrum neutralizing antibodies. This brings difficulties to the diagnosis of FMDV mainly using immunoassay technology, and it is impossible to achieve the purpose of foot-and-mouth disease prevention and control through broad-spectrum neutralizing antibodies. The present invention uses a high-throughput method to establish a single B cell antibody library to screen and obtain pig-derived single B cell antibodies with broad-spectrum neutralizing activity for type A FMDV. Summary of the invention

[0003] The purpose of the present invention is to provide a broad-spectrum neutralizing porcine monoclonal antibody against foot-and-mouth disease virus type A and application thereof.

[0004] The present invention provides a broad-spectrum neutralizing porcine monoclonal antibody against foot-and-mouth disease virus type A, comprising heavy chain variable regions CDR1, CDR2, CDR3 and light chain variable regions CDR1, CDR2, CDR3; Amino acid sequence of heavy chain variable region CDR1: GFGFSNTY (SEQ ID No. 1) Amino acid sequence of heavy chain variable region CDR2: VFTGGGAT (SEQ ID No. 2) Amino acid sequence of heavy chain variable region CDR3: VSNRDGFGGVGNV (SEQ ID No. 3) Amino acid sequence of light chain variable region CDR1: SGSVTSLNY (SEQ ID No. 4) Amino acid sequence of light chain variable region CDR2: RTN The amino acid sequence of the light chain variable region CDR3: ALYKGSGTDTNI (SEQ ID No. 5).

[0005] Antibody PAF56 also comprises heavy chain variable region FR1, FR2, FR3 framework regions and light chain variable region FR1, FR2, FR3 framework regions; The amino acid sequence of the heavy chain variable region FR1: EEKLVESGGGLVQPGGSLSLSCVGS (SEQ ID No. 6) Amino acid sequence of heavy chain variable region FR2: MTWVRQAPGKGLEWLAS (SEQ ID No. 7) The amino acid sequence of the heavy chain variable region FR3 is: YASSVKGRFTISRDNSQNTAYLQMNSLRTEDTARYYCA (SEQ ID No. 8) The amino acid sequence of the light chain variable region FR1: QTVIQEPAMSVSLGGTVTLSCAFS (SEQ ID No. 9) Amino acid sequence of light chain variable region FR2: PSWFQQTPGQPPRTMVY (SEQ ID No. 10) The amino acid sequence of the light chain variable region FR3 is: SRPAGVPSRFSGAISGNKATLTITGAQAEDEADYFC (SEQ ID No. 11).

[0006] The amino acid sequence of the heavy chain variable region of antibody PAF56: EEKLVESGGGLVQPGGSLRLSCVGSGFGFSNTYINWVRQAPGKGLEWLAAVFTGGGATGYAGSVKGRFTISSDNSQNTAYLQMNSLITEDTARYYCVSNRDGFGGVGNVWGPGVEVVVSS (SEQ ID No. 12) The amino acid sequence of the light chain variable region of antibody PAF56 is: QTVIQEPAMSVSLGGTVTLSCAFSSGSVTSLNYPSWFQQTPGQPPRTMVYRTNSRPAGVPSRFSGAISGNKATLTITGAQAEDEADYFCALYKGSGTDTNIFGRGTHLTVL (SEQ ID No. 13).

[0007] The present invention also provides the use of the foot-and-mouth disease virus type A broad-spectrum neutralizing porcine monoclonal antibody PAF56 in preparing a drug for preventing or treating foot-and-mouth disease caused by type A foot-and-mouth disease virus, and in preparing a type A foot-and-mouth disease virus diagnostic reagent.

[0008] The antibody PAF56 provided by the present invention can simultaneously neutralize the AF72 strain of the A22 lineage, and the A / WH / CHA / 09 and A / GDMM / 2013 epidemic strains of the domestic SEA97 lineage, and has broad-spectrum neutralizing activity against type A FMDV. PAF56 recognizes antigenic site 2 of the VP2 BC loop, and the key amino acid is VP2 D72. The recognized site is highly conserved in type A FMDV. PAF56 can bind to three antigens, A / AF72, A / WH / CHA / 09 and A / GDMM / 2013, all with high affinity, which are 8.89 nM, 6.20 nM and 8.11 nM, respectively. The present invention obtains for the first time a type A-specific FMDV broad-spectrum neutralizing antibody from a natural host and identifies the key antigenic site it recognizes, providing a powerful tool for the analysis of the FMDV antigen structure and the establishment of a serological detection method. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 is the SHM distribution of four isotype antibodies in the antibody library; Figure 2 Use heatmaps for heavy and light chain VJ genes; Figure 3 To detect the expression and purification of antibody PAF56 by SDS-PAGE; Figure 4 Indirect immunofluorescence was used to detect the reactivity of PAF56 and FMDV; Figure 5 Indirect ELISA was used to detect the reactivity of PAF56 and FMDV antigens; Figure 6 The antigen epitope type of FMDV recognized by antibody PAF56 was detected by WB; Figure 7 This is the key amino acid pattern diagram of the antibody PAF56 recognition site; Figure 8 The affinity of antibody PAF56 to three A-type antigens was detected by BLI. DETAILED DESCRIPTION

[0010] The present invention will be further described below through specific implementation modes.

[0011] BHK-21 cells, HEK293F cells, and type A FMDV strains (A / AF72, A / WH / CHA / 09, A / GDMM / 2013) were all preserved by the National Foot-and-Mouth Disease Reference Laboratory. The porcine IgGH chain gene vector pVH-pcDNA3.4 and the porcine IgG λ chain gene vector pVL-pcDNA3.4 were constructed and preserved by the Host Antiviral Infection and Immunobiology Team of the Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0012] Lymphocyte separation medium (Histopaque-1077, 1.077 g / mL) and FITC Rat anti mouse IgG antibody were purchased from Sigma-Aldrich. Biotin labeling kit (EZ-Link™ Sulfo-NHS-LC-Biotin) and Polyethylenimine, Linear, MW 25000, Transfection Grade (PEI25K™) were purchased from Polysciences. One-step RT-PCR amplification kit (HiScipt II One Step RT-PCR Kit) was purchased from Nanjing Novozymes Biotech Co., Ltd. Mouse anti-swine IgG-FITC antibody was purchased from Mybiosource. Horseradish peroxidase (HRP)-labeled mouse anti-swine tag antibody was purchased from Nanjing GenScript Biotech Co., Ltd. Endotoxin-free plasmid extraction kit was purchased from Tiangen Biochemical Technology Co., Ltd.

[0013] Example 1 Preparation of broad-spectrum neutralizing porcine monoclonal antibodies against foot-and-mouth disease virus type A 1. Animal immunization and establishment of a porcine FMDV-specific antibody library A healthy piglet (3 months old) with negative foot-and-mouth disease antibody was selected and immunized with O / HN / CHA / 93 inactivated vaccine at a dose of 5 µg / head through neck intramuscular injection; after an interval of 28 days, it was immunized again with the same dose of O / HN / CHA / 93 inactivated vaccine; after an interval of 129 days between the second immunization, it was immunized with O type (O / 18074 and O / xizang / CN / 99) and A type (A / AF72 and A / WH / CHA / 09) inactivated vaccines, with each antigen at 5 µg / head.

[0014] 250 mL of anticoagulated blood was collected from animals 5 days after inactivated vaccine immunization, and PBMCs were separated according to the instructions for lymphocyte separation medium. 3 mL of 1640 medium was taken to resuspend PBMCs in a centrifuge tube, and mouse anti-pig antibodies (IgM, CD14, CD3, CD335) were added, and incubated on ice for 30 min; after washing twice, Goat Anti-Mouse IgG MicroBeads were added, and incubated on ice for 30 min; after negative screening by LD column, the enriched B cells were divided into 2 sample tubes and 1 control tube, and 5 μL FITC Rat antimouse IgG was added to all 3 tubes, and biotin-labeled A / AF72 146S antigen was added to the sample tube, and incubated on ice for 20 min; finally, Anti-Biotin APC was added, and the cells were washed after incubation on ice for 20 min; the cells were resuspended in 1640 medium, and A-FMDV-Biotin specifically bound to B cells. The enriched A / AF72-specific B cells were resuspended in PBS and immediately subjected to single-cell capture and antibody library construction using the Chromium Next GEM Single Cell 5' Kit v2 (10x Genomics) (PN-1000263).

[0015] Five days after the booster immunization with type A inactivated vaccine, anticoagulated blood was collected from the animals to separate PBMCs. After enrichment of B cells, staining and flow sorting were performed to sort all antigen-specific B cells into flow tubes for sequencing of antibody variable region genes. The porcine type A FMDV-specific antibody library was successfully obtained by high-throughput sequencing. Table 1 shows the capacity of the antibody library. The A / AF72-specific antibody library obtained 8883 pairs of sequences, including IgG, IgA, IgD, and IgE, of which 8060 pairs were IgG, accounting for 90%, as shown in Table 1. The somatic hypermutation rate SHM of IgA and IgE was 0.10, and the SHM of IgD and IgG was 0.07, as shown in Table 1. Figure 1 The usage of V and J genes of light and heavy chains can be found in Figure 2 .

[0016] 2. Construction of expression plasmid and expression and purification of antibodies One IgG strain was selected from them and named PAF56. The heavy chain and light chain variable region gene sequences of the antibody were codon optimized by GenScript Incorporation (www.genscript.com) with reference to CHO-S cells (using Cricetulus griseus), and a signal peptide was added at the front end, referring to the literature [Wei Delong. Preparation of PRRSV-specific monoclonal antibodies based on single B cell antibody technology [D]. Chinese Academy of Agricultural Sciences, 2021. DOI: 10.27630 / d.cnki.gznky.2020.000282.]. The heavy chain synthetic gene was inserted into the pCH-pcDNA 3.4 expression vector containing the porcine IgG1 heavy chain constant region gene with a tandem HA tag and a His tag at the C-terminus through the Not Ⅰ and BbvC Ⅰ restriction sites; the porcine IgG λ chain synthetic gene was inserted into the pVL-pcDNA3.4 vector containing the porcine IgG λ chain gene through the Not Ⅰ and Ale Ⅰ restriction sites, according to the literature [Li K, Zhu G, Zhou S, et al. Isolation and characterizationof porcine monoclonal antibodies revealed two distinct serotype-independent epitopes on VP2 of foot-and-mouth disease virus[J].J GenVirol. 2021;102(7):10.1099 / jgv.0.001608]. The recombinant expression plasmids of the antibody heavy chain and light chain were transformed into E. coli JM109 competent cells for amplification, and a single positive colony was picked to proliferate overnight in Amp-resistant LB culture medium, and extracted and purified using the EndoFree maxi plasmid kit (Tiangen). The heavy chain / light chain plasmid was transfected into HEK293F cells using PEI at a mass ratio of 2:3; after 6-7 days of culture, the cell supernatant was collected and purified using Ni-NTA affinity chromatography media, and the expression effect of the antibody was verified by SDS-PAGE.

[0017] The antibody PAF56 plasmid was expressed in HEK293F cells, purified by affinity chromatography, and verified by SDS-PAGE. The results showed that the porcine IgG molecule was successfully expressed, with a heavy chain molecular weight of about 50 KDa and a light chain molecular weight of about 25 KDa. Figure 3 .

[0018] Example 2 Indirect immunofluorescence assay (IFA) to detect antibody reactivity A / AF72 virus solution was inoculated into BHK-21 cells in 24-well cell culture plates at a dose of MOI = 1, and a blank control was set up. After incubation at 37 °C for 3 h to 4 h, pre-cooled fixative (methanol: acetone = 1:1) was added and fixed at room temperature for 30 min, and indirect immunofluorescence detection was performed according to conventional methods. The primary antibody was the expressed antibody (5 µg / mL), and the secondary antibody was FITC-labeled rabbit anti-swine IgG.

[0019] IFA test results showed that the antibody PAF56 could bind to BHK cells infected with A / AF72 virus, and specific green fluorescence appeared ( Figure 4 ) are antibodies reactive to type A FMDV.

[0020] Example 3 Indirect ELISA to detect antibody reactivity The A / AF72 inactivated antigen was added to the ELISA plate at a dose of 100 ng / well and coated on the ELISA plate overnight at 4°C; the antibody to be tested was diluted to 20 µg / mL and added to the ELISA plate in 10 gradients of 2-fold dilution, PBS was set as a negative control, and incubated at 37°C for 1 hour. 100 µL of rabbit anti-swine IgG-HRP antibody (1:5000 dilution) was added to each well and allowed to react at 37°C for 30 minutes. TMB substrate was added to develop color at 37°C for 15 minutes. After the reaction was terminated, the OD was detected by an ELISA reader. 450 When the antibody concentration is diluted to 5 µg / mL, P / N ≥ 2.1 is considered positive (P is the OD value of two replicate wells at each dilution of the antibody to be tested). 450 The average value of nm, N is the OD of all wells in the PBS control group 450 nm values).

[0021] The results of indirect ELISA showed that when the antibody concentration was diluted to 5 µg / mL and above, the OD 450 nm value is higher than Cut Off value ( Figure 5 ), Cut Off value is CO (positive judgment value), CO = 2.1 × N (N is the negative control OD 450 nm value), and can react specifically with A / AF72 antigen.

[0022] Example 4 Neutralization test to detect antibody neutralization activity The antibody to be tested was diluted two-fold in 8 wells of a 96-well plate; 50 μL of virus dilution (titer 200 TCID 50 After incubation at 37°C for 1 h, 100 μL of BHK-21 cell suspension (density 1×10 6 / mL). After 48 h to 72 h of incubation, observe CPE, calculate the neutralization titer of serum or antibody according to the Reed-Muench method, and calculate the neutralization potency of the antibody (IC50 = antibody concentration / reciprocal of neutralization titer). If IC50 ≤ 50 µg / mL, it can be determined as a neutralizing antibody.

[0023] The neutralization efficacy of antibody PAF56 was determined by virus neutralization test. The results showed that antibody PAF56 could neutralize three strains of type A FMDV (A / AF72, A / WH / CHA / 09 and A / GDMM / 2013), but could not neutralize type O O / 18074 and O / ZK93 strains (Table 2). This result shows that PAF56 is a broad-spectrum neutralizing antibody within type A FMDV.

[0024] Example 5 Western-blot analysis of antigen epitopes recognized by antibodies Purified A / AF72146S antigen or GST-fused structural protein VP1-3 were subjected to SDS-PAGE, and then the proteins were transferred to PVDF membrane for western blotting verification. The primary antibody was porcine monoclonal antibody PAF56 (working concentration 2µg / mL), incubated at room temperature for 2 h; the secondary antibody was Anti-pig-IgG-HRP antibody, see Figure 6 A or 6C, incubate at room temperature for 1 hour and then use an exposure meter to record exposure. The GST-fused VP1-3 monomer protein bin control was incubated with Anti-GST-HRP at room temperature for 1 hour and then exposed. Figure 6 B. The results showed that PAF56 could react with the whole antigen A / AF72, but could not react with the monomeric structural protein fused with GST, indicating that PAF56 recognized the conformation-dependent linear epitope in the AF72 antigen. Figure 6 .

[0025] Example 6 Antibody escape screening antigen mutation sites A / AF72 was diluted 10-fold to 10 -6 50 µL of each virus dilution was placed in a 96-well plate, and an equal volume of neutralizing antibody at a concentration of 5 µg / mL was added. A virus control well without antibody was set up; 100 µL of 10 5 BHK-21 cells were added at 37°C for 2-3 days after mixing. The virus with the maximum dilution in 8 wells was taken and the antibody concentration was doubled for continuous passage in a 24-well plate. The escape strains in each well of the 5th generation were harvested to extract viral RNA, the FMDV structural protein gene was amplified, and the PCR product was sent to the company for sequencing. By comparing the differences in the structural protein amino acids between the escape strain and the parent strain, the key amino acids for neutralizing antibodies to recognize the viral antigen epitopes can be found.

[0026] By screening and comparing the differences in the amino acids of the structural proteins between the neutralization antibody escape mutants and the parental strains, the key amino acids recognized by the antibody were identified. The results (Table 3) showed that the key amino acid recognized by the antibody PAF56 was VP272 (D), which is highly conserved in the A-type FMDV sequence, such as Figure 7 shown.

[0027] Example 7 Biomembrane Interferometry to Determine Antigen-Antibody Affinity Biotinylated A / WH / CHA / 09, A / AF72, and A / GDMM / 2013 antigens were diluted to 5 µg / mL, and the antibody PAF56 was diluted to 100 nM. Samples were added according to the pre-designed plate map, with 200 μL per well. The program was set up: equilibration probe (60 s), immobilization antigen (120 s), two equilibration probes (60 s each), binding antibody (300 s), and dissociation antibody (180 s). The kinetic constants of antigen-antibody binding were calculated and the binding kinetic curve was fitted, as shown in Figure 2. Figure 8 The results showed that the antibody PAF56 could bind to the three antigens A / AF72, A / WH / CHA / 09 and A / GDMM / 2013 with affinities of 8.89 nM, 6.20 nM and 8.11 nM, respectively.

Claims

1. A broad-spectrum neutralizing porcine monoclonal antibody PAF56 against foot-and-mouth disease virus type A, characterized in that: The antibody PAF56 comprises heavy chain variable regions CDR1, CDR2, CDR3 and light chain variable regions CDR1, CDR2, CDR3; Amino acid sequence of heavy chain variable region CDR1: GFGFSNTY Amino acid sequence of heavy chain variable region CDR2: VFTGGGAT The amino acid sequence of the heavy chain variable region CDR3: VSNRDGFGGVGNV Amino acid sequence of light chain variable region CDR1: SGSVTSLNY Amino acid sequence of light chain variable region CDR2: RTN The amino acid sequence of the light chain variable region CDR3 is: ALYKGSGTDTNI.

2. The foot-and-mouth disease virus type A broadly neutralizing porcine monoclonal antibody PAF56 according to claim 1, characterized in that: The antibody PAF56 also comprises heavy chain variable region FR1, FR2, FR3 framework regions and light chain variable region FR1, FR2, FR3 framework regions; Amino acid sequence of heavy chain variable region FR1: EEKLVESGGGLVQPGGSLSLSCVGS Amino acid sequence of heavy chain variable region FR2: MTWVRQAPGKGLEWLAS The amino acid sequence of the heavy chain variable region FR3 is: YASSVKGRFTISRDNSQNTAYLQMNSLRTEDTARYYCA The amino acid sequence of the light chain variable region FR1 is: QTVIQEPAMSVSLGGTVTLSCAFS The amino acid sequence of the light chain variable region FR2 is: PSWFQQTPGQPPRTMVY The amino acid sequence of the light chain variable region FR3 is: SRPAGVPSRFSGAISGNKATLTITGAQAEDEADYFC.

3. The foot-and-mouth disease virus type A broadly neutralizing porcine monoclonal antibody PAF56 according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region of the antibody PAF56 is shown in SEQ ID No. 12, and the amino acid sequence of the light chain variable region is shown in SEQ ID No.

13.

4. Use of the foot-and-mouth disease virus type A broadly neutralizing porcine monoclonal antibody PAF56 as claimed in any one of claims 1 to 3 in the preparation of a drug for preventing or treating foot-and-mouth disease caused by type A foot-and-mouth disease virus.

5. Use of the broadly neutralizing porcine monoclonal antibody PAF56 against foot-and-mouth disease virus type A as claimed in any one of claims 1 to 3 in the preparation of a detection or diagnostic reagent for foot-and-mouth disease virus type A.

Citation Information

Patent Citations

  • A type foot-and-mouth disease virus neutralizing antibody HY2 as well as preparation method and application thereof

    CN117964746A

  • Foot and mouth disease virus Asia1 type neutralizing swine monoclonal antibody and application thereof

    CN118108837A

Cited By

  • Foot-and-mouth disease virus O-type internal broad-spectrum neutralizing swine monoclonal antibody and application thereof

    CN119264249A